Gyre Therapeutics (NASDAQ:GYRE) Stock Price Down 4% Following Insider Selling

Gyre Therapeutics, Inc. (NASDAQ:GYRE) shares dropped 4% on Tuesday following insider selling activity. The company traded as low as $11.50 and last traded at $11.56. Approximately 9,169 shares traded hands during trading, a decline of 89% from the average daily volume of 80,791 shares. The stock had previously closed at $12.04.

Specifically, Director Nassim Usman sold 20,000 shares of the business’s stock in a transaction dated Wednesday, May 1st. The shares were sold at an average price of $14.13, for a total transaction of $282,600.00. Following the sale, the director now owns 1,636 shares of the company’s stock, valued at $23,116.68. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 2.92% of the company’s stock.

Gyre Therapeutics Stock Down 3.0 %

The business has a fifty day moving average of $12.62 and a two-hundred day moving average of $16.62.

Gyre Therapeutics (NASDAQ:GYRE) last posted its earnings results on Thursday, May 9th. The company reported $0.04 earnings per share for the quarter. The firm had revenue of $27.17 million during the quarter. Analysts expect that Gyre Therapeutics, Inc. will post -0.45 earnings per share for the current year.

About Gyre Therapeutics

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.